1. Loss of smooth muscle SDF-1/CXCL12 leads to cardiac hypertrophy and aortic valve stenosis. (25th November 2020) Authors: Ghadge, S.K; Messner, M; Seiringer, H; Zeller, T; Boernigen, D; Weninger, W.J; Geyer, S.H; Sopper, S; Poelzl, G; Tepekoeylue, C; Zaruba, M.M Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P926Smooth muscle cell specific SDF-1/CXCL12 KO mice display severe cardiac hypertrophy and vascular defects. (28th August 2018) Authors: Ghadge, S K; Messner, M; Seiringer, H; Wimmer, A; Zeller, T; Boernigen, D; Poelzl, G; Zaruba, M M Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Smooth muscle cell specific ablation of CXCL12 downregulates endothelial CXCR7 leading to defective coronary arteries and cardiac hypertrophy. (14th October 2021) Authors: Messner, M; Ghadge, S K; Seiringer, H; Maurer, T; Staggl, S; Zeller, T; Mueller, C; Wenninger, W J; Geyer, S H; Sopper, S; Krogsdam, A; Poelzl, G; Bauer, A; Zaruba, M M Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗